CBN β€” Cannabinol

What is CBN? Formation from THC degradation, why elevated CBN indicates product deterioration, GMP stability significance and limited clinical evidence.

Cannabinoid LibraryπŸ• 2 minGary McPolin Β· ECI
Gary McPolin
Founder, European Cannabis Institute Β· Senior CQV and GMP Consultant Β· 20+ years pharmaceutical manufacturing
Last reviewed: June 2026 Β· EU GMP Annex 1 (2022) aligned
Clinical Disclaimer

This page is an educational summary and does not constitute clinical guidance or a recommendation for use. Prescribing, dosing and treatment decisions should be made on the basis of individual patient assessment, current clinical guidelines and the treating healthcare professional's judgement.

What is CBN?

CBN (C₂₁H₂₆Oβ‚‚) is a naturally occurring cannabinoid in Cannabis sativa. CBN is formed by oxidative degradation of THC β€” not directly biosynthesised. Accumulates during storage with light, oxygen and heat exposure. Fresh cannabis contains very little CBN; aged or improperly stored material has elevated CBN and reduced THC.

Pharmacology

CBN is a weak partial CB1 agonist (~10% of THC potency). Mildly psychoactive only at very high doses. Has been marketed as a sleep aid but controlled evidence is absent β€” a 2023 trial found CBN did not outperform placebo for sleep quality in healthy adults.

Current Evidence

No clinical trial evidence supports use of CBN for any indication as of 2026. All marketed benefits are preclinical or anecdotal.

GMP Relevance

CBN is critical as a stability-indicating parameter. Elevated CBN in a finished product indicates THC degradation from improper storage, excessive age, inadequate packaging or manufacturing failures including over-decarboxylation. EU GMP specifications for THC-dominant products must include a CBN limit. ICH Q1A stability programmes should be designed to detect CBN accumulation over the intended shelf life.

Regulatory Status

CBN is not independently scheduled as a controlled substance in most European jurisdictions as a component of cannabis starting material. Pharmaceutical preparations require EU GMP manufacturing standards. Specifications should include identity, purity and assay by validated HPLC.

See the Cannabis Glossary for definitions of related cultivation, extraction and quality terms.

References

  • Corroon J. Cannabinol and Sleep. Cannabis Cannabinoid Res. 2021.
  • ICH Q1A(R2) β€” Stability Testing of New Drug Substances and Products.
  • EU GMP Annex 1 (2022) β€” product specifications and stability.
Free Assessment
Test your GMP readiness

45 questions, 12 minutes. Score your facility across 10 GMP dimensions with instant recommendations.

Start Free Assessment β†’
Get Certified
Turn knowledge into credentials

CCGP, CCPS and CCVP β€” professional cannabis GMP certifications developed for European licensed markets.

View Certifications β†’
GMP Templates
Download and implement

CCS, VMP, SMF, EMPQ β€” Annex 1 (2022) aligned templates with cannabis-specific content, ready to complete.

View Templates β†’
Stay Informed
Join ECI membership

Premium articles, intelligence reports, regulatory map and priority access to new tools and assessments.

Related reading

Article
THC Explained
Read β†’
Article
CBD Explained
Read β†’
Article
Contamination Control
Read β†’